ECSP12012181A - Nuevos péptidos y métodos para su preparación y uso - Google Patents

Nuevos péptidos y métodos para su preparación y uso

Info

Publication number
ECSP12012181A
ECSP12012181A ECSP12012181A ECSP12012181A EC SP12012181 A ECSP12012181 A EC SP12012181A EC SP12012181 A ECSP12012181 A EC SP12012181A EC SP12012181 A ECSP12012181 A EC SP12012181A
Authority
EC
Ecuador
Prior art keywords
gip
receptor
preparation
methods
gluc
Prior art date
Application number
Other languages
English (en)
Inventor
Fernadez Jorge Alsina
Krister Bengt Bokvist
Lili Guo
John Philip Mayer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44041636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012181(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP12012181A publication Critical patent/ECSP12012181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al campo de tratamiento de diabetes y se refiere a péptidos que presentan actividad para tanto el receptor del péptido insulinotrópico dependiente de la glucosa (GIP-R) como el receptor del péptido-1 similar al glucagón (GLP-1-R) y son selectivos sobre el receptor del glucagón (Gluc-R). Se proporcionan específicamente análogos de GIP con sustituciones de aminoácido introducidas para modular la actividad para tanto GIP-R como GLP-1-R y mantener la selectividad sobre Gluc-R.
ECSP12012181 2010-03-26 2012-09-26 Nuevos péptidos y métodos para su preparación y uso ECSP12012181A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31785010P 2010-03-26 2010-03-26

Publications (1)

Publication Number Publication Date
ECSP12012181A true ECSP12012181A (es) 2012-11-30

Family

ID=44041636

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012181 ECSP12012181A (es) 2010-03-26 2012-09-26 Nuevos péptidos y métodos para su preparación y uso

Country Status (26)

Country Link
US (1) US8815811B2 (es)
EP (1) EP2552471B1 (es)
JP (1) JP5887335B2 (es)
KR (1) KR101407775B1 (es)
CN (1) CN102821779B (es)
AR (1) AR080592A1 (es)
AU (1) AU2011232597B2 (es)
BR (1) BR112012024373A2 (es)
CA (1) CA2794664A1 (es)
CL (1) CL2012002635A1 (es)
CO (1) CO6630128A2 (es)
CR (1) CR20120457A (es)
DO (1) DOP2012000244A (es)
EA (1) EA022489B1 (es)
EC (1) ECSP12012181A (es)
ES (1) ES2568796T3 (es)
GT (1) GT201200263A (es)
MA (1) MA34077B1 (es)
MX (1) MX2012011127A (es)
PE (1) PE20130523A1 (es)
PH (1) PH12012501899A1 (es)
SG (1) SG184289A1 (es)
TN (1) TN2012000432A1 (es)
TW (1) TWI535450B (es)
WO (1) WO2011119657A1 (es)
ZA (1) ZA201206832B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
IN2014MN02304A (es) 2012-05-03 2015-08-07 Zealand Pharma As
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
IN2015DN00544A (es) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
WO2014161835A1 (en) 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
EP2986313B1 (en) 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
SI3004155T1 (sl) 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
TWI582109B (zh) * 2015-01-09 2017-05-11 美國禮來大藥廠 Ｇｉｐ及ｇｌｐ－１共促效劑化合物
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
EP3699187A1 (en) * 2019-02-21 2020-08-26 Universite D'angers Peptide targeting gip and glp-2 receptors for treating bone disorders
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
IL294955A (en) * 2020-01-23 2022-09-01 Lilly Co Eli Cobalt-agonist gip/glp1 compounds
EP4110800A1 (en) 2020-03-06 2023-01-04 Sanofi Peptides as selective gip receptor agonists
AU2021233745B2 (en) * 2020-03-11 2024-05-02 Anygen Co., Ltd. Composition for anti-diabetes and anti-obesity comprising novel compound
IL306122B2 (en) * 2021-05-28 2026-01-01 Guangdong Raynovent Biotech Co Ltd Preparation and use of polypeptide
EP4345105A4 (en) * 2021-06-01 2025-04-23 Nanjing Zhihe Medicine Technology Co., Ltd Polypeptide derivative with dual targeted activation of GLP-1R and GIPR, manufacturing process therefor and use thereof
CN115594752A (zh) * 2021-07-07 2023-01-13 成都奥达生物科技有限公司（Cn） 一种长效双激动剂化合物
KR20240055069A (ko) 2021-09-06 2024-04-26 사노피 효력있는 선택적 gip 수용체 작용제로서의 신규 펩티드
KR20230037391A (ko) * 2021-09-09 2023-03-16 애니젠 주식회사 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물
AU2022392980B2 (en) * 2021-11-19 2025-12-18 Jiangsu Deyuan Pharmaceutical Co., Ltd. Stapled peptide and use thereof
WO2024020388A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
CN119894921A (zh) 2022-09-15 2025-04-25 伊莱利利公司 Gip和glp-1双重激动剂化合物
JP2026502943A (ja) 2022-12-30 2026-01-27 アルギファルマ エーエス 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
EP4714434A1 (en) 2023-05-19 2026-03-25 Aulbio Co., Ltd. Microsphere comprising thyrazepatide, method for preparing same, and pharmaceutical composition comprising same
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
TW202517291A (zh) 2023-06-30 2025-05-01 丹麥商西蘭製藥公司 組合療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
CA2607566A1 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2006121904A1 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
CN102105159B (zh) * 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
AU2009280021B2 (en) 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
WO2010016940A2 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트

Also Published As

Publication number Publication date
TW201201829A (en) 2012-01-16
EA201270723A1 (ru) 2013-01-30
MX2012011127A (es) 2012-10-15
JP2013523647A (ja) 2013-06-17
GT201200263A (es) 2013-12-05
US20110237503A1 (en) 2011-09-29
CN102821779B (zh) 2015-03-11
CN102821779A (zh) 2012-12-12
ZA201206832B (en) 2014-03-26
DOP2012000244A (es) 2013-02-15
SG184289A1 (en) 2012-11-29
EP2552471B1 (en) 2016-03-16
ES2568796T3 (es) 2016-05-04
AU2011232597A1 (en) 2012-08-30
BR112012024373A2 (pt) 2017-01-10
TWI535450B (zh) 2016-06-01
PE20130523A1 (es) 2013-04-25
EP2552471A1 (en) 2013-02-06
CL2012002635A1 (es) 2012-12-21
MA34077B1 (fr) 2013-03-05
AU2011232597B2 (en) 2015-01-29
CR20120457A (es) 2012-10-16
KR20120133402A (ko) 2012-12-10
US8815811B2 (en) 2014-08-26
PH12012501899A1 (en) 2013-01-14
CO6630128A2 (es) 2013-03-01
AR080592A1 (es) 2012-04-18
TN2012000432A1 (en) 2014-01-30
CA2794664A1 (en) 2011-09-29
EA022489B1 (ru) 2016-01-29
JP5887335B2 (ja) 2016-03-16
WO2011119657A1 (en) 2011-09-29
KR101407775B1 (ko) 2014-06-17

Similar Documents

Publication Publication Date Title
ECSP12012181A (es) Nuevos péptidos y métodos para su preparación y uso
NZ612297A (en) Glucagon analogs exhibiting gip receptor activity
JOP20200119A1 (ar) مركبات مساعد مشترك من gip وglp-1
UY33462A (es) Analogos de glucagon
MX2019006260A (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad.
AR091477A1 (es) Analogos de glucagon que presentan actividad de receptor de gip
MX386803B (es) Agonistas de receptor de glp-1/glucagón de acción prolongada.
EA201690660A1 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
CO7400885A2 (es) Análogos de glucagón
GT201300319A (es) Coagonistas del receptor de glucagón / glp-1
ECSP12011593A (es) Análogos de glucagón acilados
HUE049152T2 (hu) Hosszantartó hatású GLP-1 peptidek alkalmazása
AR083528A1 (es) Analogos de peptido insulinotropico dependiente de glucosa
CL2012003641A1 (es) Compuesto analogo de glucagon que comprende sustituciones de los residuos aminoacidos en las posiciones 3 y/o 4 del glucagón nativo y que tiene actividad en el receptor de glucagon y/o el receptor de glp-1; composicion farmaceutica que comprende el compuesto; uso del compuesto para prevenir aumento de peso o promover perdida de peso en un sujeto que lo necesita.
CL2011003173A1 (es) Análogo del glucagón, agonista gip y glp-1; dímero que comprende el análogo de glucagón; conjugado con el análogo; composición que comprende dicho análogo; uso para preparar un medicamento para tratar diabetes, reducir el aumento de peso o inducir la pérdida de peso.
GT201200023A (es) Polipéptidos del factor ix modificados y usos de los mismos
UY32525A (es) Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY33372A (es) ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.
UY32523A (es) Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
ECSP15009978A (es) Análogos de glucagón
CL2009001796A1 (es) Compuestos derivados de heteroarilo-(benceno/heteroarilo) fusionados con actividad antagonista de glucagon; composicion farmaceutica; y su uso para suprimir la produccion de azucar y para la terapia o el tratamiento de la diabetes.